ValiRx PLC (AIM:VAL) shares rose 12% following news of a successful customer shipment from its subsidiary, Inaphaea BioLabs Limited.
The delivery is of patient-derived cells (PDCs), part of its new Assay Ready Reagents (ARR) range.
The ARR products are ready-to-use for assays, removing the need for customers to cultivate cells themselves.
Although the order's financial value is not significant, it validates Inaphaea's product offering and highlights a potential new revenue stream, boosting investor confidence in the company's expanding capabilities in early-stage cancer therapeutics and women's health.
The stock was up 0.18p at 1.55p.